MariMed Inc. reported its highest-ever quarterly revenue of $44.2 million for Q3 2026, marking a 5.5% increase from the previous quarter and 8.5% year-over-year growth. Adjusted EBITDA rose 18% sequentially to $4.7 million, and the company ended the quarter with its strongest cash position in over two years at $10.4 million. Key brands like Betty’s Eddies led market share gains, while retail transactions and average order value also increased. MariMed plans to leverage its brand momentum, production capacity, and cash reserves to expand market share and invest in growth, while monitoring potential federal cannabis reforms that could impact the industry.
MariMed Inc. reported its Q3 2026 earnings. For readers following Consumer Staples, here is Pluang's market snapshot as of Nov 12, 2026 01:22 WIB: Out of 63 priced US stocks, 16 rose and 46 fell. Notable movers include FIZZ at USD 36.71 (-2.16%), TSN at USD 59.04 (-2.07%) with 100% buy order activity, and JBS at USD 12.16 (-1.94%) with 100% buy order activity.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
